US FDA lifts clinical hold on Novavax's combo flu shot
Adds background in paragraphs 3,9 and 10, updates shares in paragraph 2
Nov 11 (Reuters) -The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's NVAX.O COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated to the combination shot, the company said.
Shares of the vaccine maker, which is scheduled to report third-quarter results on Tuesday, rose nearly 17% to $10.39 on Monday. They pared their gains and were last up 2%.
The Maryland-based biotech announced the clinical hold last month after a participant who had received its COVID-influenza combination vaccine had reported symptoms of motor neuropathy, or damage to the nerve cells that control muscles or movement.
The person was administered the vaccine in January last year as part of a mid-stage study.
Novavax said on Monday it had changed the participant's symptoms to amytrophic lateral sclerosis, a condition that affects nerve cells in the brain and spinal cord, in additional details provided to the U.S. health regulator.
Assessment showed the symptoms were not related to its shot, the company said.
"The information provided to the FDA supported our assessment that the serious adverse event was not related to our vaccine," said Chief Medical Officer Robert Walker.
The company will resume late-stage trial activities as quickly as possible, he said.
Shares of Novavax fell 19% when the hold was announced on Oct. 16.
The COVID vaccine is Novavax's lone marketed product after over 35 years in business and the company is banking on its combination shot and flu vaccine to drive future growth.
Novavax's traditional protein-based COVID shot offers an alternative technology to messenger RNA-based rivals from Pfizer PFE.N-BioNTech BNTX.O and Moderna MRNA.O but has failed to make a mark in the U.S. vaccine market.
In May, Novavax signed a licensing deal worth at least $1.2 billion with French drugmaker Sanofi SASY.PA for the COVID vaccine, gaining access to much-needed liquidity.
Last year, the company had raised doubts about its ability to remain in business.
Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri and Sriraj Kalluvila
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
